Ranked #1,936 of 8,699 institutional investors
Bain Capital Life Sciences Investors, LLC
Boston, MA
$1.35B
US stock portfolio at live prices · today −$29.9M (−2.17%)
Live prices, last trade 12:49 PM ET
- Value at quarter end (Q3 2026)
- $1.49B
- Change from Q2 2026
- −$192.2M (−11.43%)
- Positions
- 19 · 4 new, 2 sold out
- Filed
- Nov 16, 2026
Not counted in the ranking: none$298M of holdings we could not match to a US listing are included at their reported quarter-end value.
Holdings
Q3 2026 13F, live pricesKLRA 19.1%HTFL 15.2%ADRX 6.70%TARS 6.07%SVRA 5.58%
| Stock | Shares | Value, live | % of portfolio | vs Q2 2026 |
|---|---|---|---|---|
| KLRA Kailera Therapeutics, Inc. | 22,583,268 | $257M | 19.1% | Unchanged |
| HTFL Heartflow, Inc. | 4,448,158 | $205M | 15.2% | Reduced −47% |
| ADRX ADARx Pharmaceuticals, Inc. | 6,728,970 | $90.2M | 6.70% | New |
| TARS Tarsus Pharmaceuticals, Inc. | 1,096,141 | $81.8M | 6.07% | New |
| SVRA Savara Inc. | 17,600,621 | $75.2M | 5.58% | Unchanged |
| COAG Hemab Therapeutics Holdings, Inc. | 1,650,000 | $65.5M | 4.86% | Unchanged |
| SLDB Solid Biosciences Inc. | 9,808,819 | $61.2M | 4.54% | Unchanged |
| OLMA Olema Oncology, Inc. | 7,085,249 | $50.4M | 3.74% | Unchanged |
| DYN Dyne Therapeutics, Inc. | 1,900,000 | $29.9M | 2.22% | New |
| XFOR X4 Pharmaceuticals, Inc. | 7,967,454 | $23.7M | 1.76% | Unchanged |
| FRNM Freenome, Inc. | 2,365,459 | $22.4M | 1.66% | New |
| CABA Cabaletta Bio, Inc. | 21,209,188 | $20.3M | 1.51% | Added +23% |
| CCCC C4 Therapeutics, Inc. | 7,171,910 | $17.9M | 1.33% | Unchanged |
| ANNX Annexon, Inc. | 4,437,731 | $13.9M | 1.03% | Unchanged |
| IRON Disc Medicine, Inc. | 141,234 | $10.6M | 0.79% | Unchanged |
| AVIR Atea Pharmaceuticals, Inc. | 2,075,639 | $8.1M | 0.60% | Unchanged |
| RPID Rapid Micro Biosystems, Inc. | 8,434,560 | $6.2M | 0.46% | Unchanged |
| KYTX Kyverna Therapeutics, Inc. | 1,312,000 | $5.6M | 0.41% | Reduced −55% |
| XLO Xilio Therapeutics, Inc. | 664,021 | $4.9M | 0.36% | Unchanged |